The author explains how the pharmaceutical companies must find a better way to increase their output of truly new drugs for the benefit of patients and for their business survival. He highlights a general perspective from within pharmaceutical research as it pertains to research advances in chemistry, biology, pharmacology, pharmacokinetics and toxicology that, if well integrated, stands to put the industry on a productive path.